Sidley Represents AdvanCell in Collaboration and Exclusive Licensing Agreement With 48Hour Discovery

Sidley represented AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, on its collaboration and exclusive licensing agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic, with an initial focus on a gastrointestinal cancer that currently lacks effective treatment options. The collaboration combines 48Hour Discovery’s peptide discovery platform with AdvanCell’s deep expertise in 212Pb radioligand development and its scalable, integrated platform spanning isotope supply and modular manufacturing, supporting a rapid and repeatable path into the clinic and the expansion of AdvanCell’s targeted alpha therapy pipeline. Under the agreement, AdvanCell obtained exclusive worldwide rights to develop and commercialize the program.

The Sidley team was led by Alison Lehner (Emerging Companies and Venture Capital) and included Sophia Iams (Technology and Life Sciences Transactions).